Antihuman CD44 antibody BJ18 inhibits platelet phagocytosis by correcting aberrant FcɣR expression and M1 polarization in immune thrombocytopenia
Authors:
- 1 June 2021
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 95, 107502
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 48 references indexed in Scilit:
- Expression-based genome-wide association study links the receptor CD44 in adipose tissue with type 2 diabetesProceedings of the National Academy of Sciences, 2012
- The Cell Biology of PhagocytosisAnnual Review of Pathology: Mechanisms of Disease, 2012
- High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcγ receptors on monocytes in patients with primary immune thrombocytopeniaBlood, 2011
- CD44-specific antibody treatment and CD44 deficiency exert distinct effects on leukocyte recruitment in experimental arthritisBlood, 2008
- Critical but divergent roles for CD62L and CD44 in directing blood monocyte trafficking in vivo during inflammationBlood, 2008
- Elevated levels of serum CD44 and E-cadherin predict an unfavourable outcome in myelodysplastic syndromesLeukemia, 2006
- CD44 is a phagocytic receptorBlood, 2006
- Anti-interleukin-1 and anti-CD44 interventions producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblastsArthritis & Rheumatism, 2000
- Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon.Journal of Cell Biology, 1995
- CD44 is the principal cell surface receptor for hyaluronateCell, 1990